Revance price target lowered to $10 from $35 at Barclays

Barclays lowered the firm’s price target on Revance to $10 from $35 and keeps an Overweight rating on the shares. The analyst sees the generics and biosimilars outlook as the “healthiest in years,” with easing generic deflation and rising loss of exclusivity opportunities. The firm upgraded the specialty pharmaceuticals industry to Positive.